Salute e Benessere
Sobi Q3 2025 report: Accelerated growth and portfolio momentum
* The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant, Vonjo and Zynlonta, and royalty on Sanofi's sales of Altuviiio and Beyfortus.
Investors, analysts, and the media are invited to a conference call on the same day at 13:00 CEST , 12:00 BST , and 07:00 EDT . The call will include a presentation of the results and a Q&A session.
The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.
To participate in the conference call, please use the following dial-in details:
Sweden : +46 8 5051 0031
United Kingdom : +44 207 107 06 13
United States : +1 631 570 56 13
For other countries, please find the details here.
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:00 CEST on 20 October 2025.
Gerard Tobin
Head of Investor Relations
This information was brought to you by Cision http://news.cision.com.
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-q3-2025-report--accelerated-growth-and-portfolio-momentum,c4252738
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/sobi-q3-2025-report-accelerated-growth-and-portfolio-momentum-302588818.html